Literature DB >> 12095810

Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report.

Gildo Y Fujii1, Eugene de Juan, Dante J Pieramici, Mark S Humayun, Steve Phillips, Sandra M Reynolds, Michele Melia, Andrew P Schachat.   

Abstract

PURPOSE: To report the 1-year visual outcomes and incidence of persistent and recurrent choroidal neovascularization (CNV) after limited macular translocation (LMT) for subfoveal CNV in patients with age-related macular degeneration (ARMD).
DESIGN: Interventional case series.
METHODS: Retrospective review of 102 consecutive eyes of 101 patients that had the inferior limited macular translocation procedure for subfoveal choroidal neovascularization secondary to ARMD. The outcome measures were visual acuity at 12 months after surgery, change in visual acuity from baseline, the proportion of eyes with moderate (3 or more lines) or severe (6 or more lines) visual acuity loss, and cumulative incidence of persistent or recurrent CNV and its impact on visual acuity. Cumulative incidence was estimated using Kaplan-Meier survival analysis methods. Association between persistence and recurrence of CNV and the Snellen visual acuity recorded at each follow-up visit was evaluated using the Wilcoxon rank-sum test.
RESULTS: Eighty-six (84.3%) of 102 eyes completed the 1-year follow-up. By 12 months postoperatively, 35 (40.7%) of the 86 eyes achieved visual acuity of 20/100 or better while 34 (39.5%) of the 86 eyes experienced 2 or more Snellen lines of visual improvement. In the 52 eyes with effective translocation and complete laser photocoagulation of the CNV complex with sparing of the sensory fovea, the estimated incidence of recurrence was 34.6% at 12 months (95% confidence interval of 21%-48%). Sixty-five percent of the recurrences were subfoveal and caused a decrease in visual acuity. There was a trend toward worse median change in visual acuity in eyes with persistent or recurrent CNV.
CONCLUSIONS: Limited macular translocation for the treatment of subfoveal CNV secondary to ARMD is associated with improvement in visual acuity in approximately 39.5% of eyes and enables complete laser photocoagulation of the neovascular complex with sparing of the sensory macula in approximately 60.4% of eyes that complete 1 year follow-up. Persistence and recurrence of CNV are common after LMT and are important causes of vision loss. Further studies are warranted to more precisely evaluate the risks and benefits of LMT in ARMD.

Entities:  

Mesh:

Year:  2002        PMID: 12095810     DOI: 10.1016/s0002-9394(02)01511-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

1.  Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery.

Authors:  W-M Chan; D S C Lam; D T L Liu; T-H Wong; K S C Yuen
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration.

Authors:  Michael J Potter; Shelagh M Szabo
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

3.  Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.

Authors:  Puran S Bora; Zhiwei Hu; Tongalp H Tezel; Jeong-Hyeon Sohn; Shin Goo Kang; Jose M C Cruz; Nalini S Bora; Alan Garen; Henry J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-14       Impact factor: 11.205

4.  The end of submacular surgery for age-related macular degeneration? A meta-analysis.

Authors:  Christiane I Falkner; Harald Leitich; Florian Frommlet; Peter Bauer; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-04       Impact factor: 3.117

5.  Recurrent choroidal neovascularization after macular translocation surgery with 360-degree peripheral retinectomy.

Authors:  Claxton A Baer; Catherine Bowes Rickman; Sunil Srivastava; Goldis Malek; Sandra Stinnett; Cynthia A Toth
Journal:  Retina       Date:  2008-10       Impact factor: 4.256

Review 6.  Treatment of age-related macular degeneration.

Authors:  Andrew C Browning; Winfried M Amoaku; Harminda S Dua
Journal:  J R Soc Med       Date:  2004-04       Impact factor: 18.000

7.  Treatment of age-related macular degeneration: focus on ranibizumab.

Authors:  Martin S Spitzer; Focke Ziemssen; Karl U Bartz-Schmidt; Faik Gelisken; Peter Szurman
Journal:  Clin Ophthalmol       Date:  2008-03

8.  Long-term results after limited macular translocation surgery for wet age-related macular degeneration.

Authors:  Hisaaki Oshima; Takeshi Iwase; Kohei Ishikawa; Kentaro Yamamoto; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-05-23       Impact factor: 3.240

Review 9.  Age-related macular degeneration: beyond anti-angiogenesis.

Authors:  David L Kent
Journal:  Mol Vis       Date:  2014-01-06       Impact factor: 2.367

Review 10.  Major challenges in vitreoretinal surgery.

Authors:  Yijun Hu; Shibo Tang
Journal:  Taiwan J Ophthalmol       Date:  2014-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.